Otofonix Encore vs Signia Pure C&G IX
Side-by-side HearAdvisor lab results with SoundGrades, expert pick badges, and the same visualizations we use in product reviews.

Otofonix Encore
The Otofonix Encore is a behind-the-ear prescription hearing aid priced at $295, placing it in the budget tier of the prescription category. In our lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking 35th out of 36 prescription hearing aids tested. Sound performance presents significant challenges across most metrics. Speech clarity scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.32 and 0.96 points below category averages respectively. Music streaming capability is essentially absent at 0.0/5, and own-voice comfort is notably limited at 0.1/5 in the tuned configuration—2.65 points below the category average. The one bright spot is feedback handling, which scores an excellent 4.7/5. While this falls just 0.01 points below the category average, it represents strong absolute performance that should minimize whistling issues during daily use. This device runs on disposable batteries. At this price point, shoppers should be aware that the RxEars Rxi offers substantially better sound performance (4.09/5) in the same price range. The Otofonix Encore may suit budget-conscious consumers who prioritize feedback stability over speech clarity and streaming features, but our testing suggests most users would benefit from considering higher-performing alternatives within this price tier.
Choice

Signia Pure C&G IX
The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, currently available at $3,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.1/5, ranking #20 among 36 prescription hearing aids tested. This device demonstrates consistent strength across multiple performance areas. Speech in quiet scored a solid 4.0/5, sitting 0.65 points above the category average. Speech in noise performance, while above the category average by 0.25 points, remains mixed in absolute terms at 2.2/5—a common challenge across prescription devices. Feedback handling is a standout feature, achieving a perfect 5.0/5 and exceeding the already-high category average. Own-voice comfort scores a solid 3.2/5, running 0.45 points above the category average, which suggests good occlusion management. Music streaming performs solidly at 3.0/5, also above average for the category by 0.36 points. The device supports both iPhone and Android streaming along with hands-free functionality. Professional tuning yields meaningful improvement, with the normalized score increasing from 4.0/5 to 4.5/5. Buyers seeking top-tier performance in this price range should note that competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) scored higher in our testing. The Pure C&G IX may suit those who prioritize reliable feedback control and balanced everyday performance over maximum speech-in-noise capability.
We independently review each item we recommend and appreciate your trust and support. When you buy through our links, we may earn a commission. Learn More.
Performance metrics
Scale 1-5 (Tuned)
Lab metric by fit
Scale 1-5 (Tuned)
Speech level
Adjust input dB (Tuned)
Amplification (REIG)
Insertion gain at 65 dB (Tuned)
Audio scenes
Using MUSHRA scenes (Tuned)
Fitting configuration for tuned fit